Theravance Biopharma Inc.(TBPH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TBPH Theravance Biopharma Inc.

休市中 07-31 16:00:00 EDT

16.86

+0.01

+0.06%

盘后16.86

+0.000.00%

17:21 EDT

最高16.88	最低16.85	成交量36.97万
今开16.87	昨收16.85	日振幅0.18%
总市值8.74亿	流通市值4.09亿	总股本5,183万
成交额623.45万	换手率1.52%	流通股本2,427万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TBPH","market":"US","secType":"STK","nameCN":"Theravance Biopharma Inc.","latestPrice":16.86,"timestamp":1785528000000,"preClose":16.85,"halted":0,"volume":369695,"hourTrading":{"tag":"盘后","latestPrice":16.86,"preClose":16.86,"latestTime":"17:21 EDT","volume":22560,"amount":380361.6,"timestamp":1785532882801,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0005934718100889027,"floatShares":24272900,"shares":51828254,"eps":2.21098,"marketStatus":"休市中","change":0.01,"latestTime":"07-31 16:00:00 EDT","open":16.87,"high":16.88,"low":16.85,"amount":6234520.95281,"amplitude":0.00178,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.21098,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1400212800000,"exchange":"NASDAQ","adjPreClose":16.85,"postHourTrading":{"tag":"盘后","latestPrice":16.86,"preClose":16.86,"latestTime":"17:21 EDT","volume":22560,"amount":380361.6,"timestamp":1785532882801,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.860762,"impliedVol":0.0059,"impliedVolPercentile":0.0319},"requestUrl":"/m/hq/s/TBPH/tweets","defaultTab":"tweets","newsList":[{"id":"1146396391","title":"Theravance Biopharma：若交易在特定情况下终止，公司将向Zymeworks支付3250万美元终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1146396391","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146396391?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:38","pubTimestamp":1782729520,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. 披露，根据其与Zymeworks Inc.达成的协议条款，若交易在特定情况下被终止，公司将需向Zymeworks支付一笔高达3250万美元的终止费用。\n此项财务安排明确了交易未能完成时的责任归属，为双方的合作设定了清晰的退出机制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007","ZYME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136977316","title":"Theravance Biopharma盘前重挫3.3%，Zymeworks拟以每股17美元现金加或有价值权收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1136977316","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136977316?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:04","pubTimestamp":1782727469,"startTime":"0","endTime":"0","summary":"生物制药公司Theravance Biopharma Inc.的股价在盘前交易时段遭遇显著下滑，跌幅达到3.3%。此前，该公司宣布已与Zymeworks Inc.达成收购协议。根据协议条款，Zymeworks将以每股17美元的现金价格收购Theravance Biopharma的全部流通股，此外，交易还包含一项或有价值权安排。此项收购案为Theravance Biopharma的股东提供了直接的现金对价，并结合了基于未来特定里程碑达成情况而可能支付的额外价值。交易细节的公布通常会引起股价波动，此次盘前下跌正是市场对收购条款进行初步定价与权衡的直接体现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","ZYME","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194792603","title":"Theravance Biopharma股东将就Ampreloxetine变现净收益的80%获得或有价值权","url":"https://stock-news.laohu8.com/highlight/detail?id=1194792603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194792603?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:02","pubTimestamp":1782727338,"startTime":"0","endTime":"0","summary":"Theravance Biopharma公司宣布，其股东将有权获得一项或有价值权（CVR），该权利与Ampreloxetine资产变现所产生的净收益挂钩。具体而言，股东将有权分享该资产净收益的80%。这一安排旨在将未来潜在的价值创造直接回馈给公司股东。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4007","BK4139","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118910752","title":"Theravance Biopharma预计重组行动将产生500万至700万美元一次性现金遣散成本","url":"https://stock-news.laohu8.com/highlight/detail?id=1118910752","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118910752?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:44","pubTimestamp":1778157864,"startTime":"0","endTime":"0","summary":"生物制药公司Theravance Biopharma宣布，因实施重组计划，预计将承担约500万至700万美元的一次性现金遣散费用。此次重组行动旨在优化公司运营结构，相关成本主要涉及员工离职补偿。该笔费用将作为特殊项目计入财务报表，不影响公司核心业务的持续经营能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173514028","title":"Theravance Biopharma Inc宣布重大重组：将终止研发职能并大幅缩减行政开支","url":"https://stock-news.laohu8.com/highlight/detail?id=1173514028","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173514028?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:39","pubTimestamp":1778157573,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc近日公布了一项重大战略调整方案，公司决定全面终止研发部门运作，并对行政管理部门进行大规模精简。这一重组举措标志着该生物制药企业将彻底转变其运营模式与发展方向。根据公告内容，此次重组涉及两个核心层面：研发职能的逐步退出与行政管理职能的实质性压缩。这项重大调整预计将对公司未来业务布局产生深远影响。随着研发职能的退出，Theravance Biopharma将重新聚焦于现有产品的商业化运营与市场拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164724538","title":"Theravance Biopharma预计Q3将实现约7000万美元全速运转成本节约","url":"https://stock-news.laohu8.com/highlight/detail?id=1164724538","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164724538?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:39","pubTimestamp":1778157555,"startTime":"0","endTime":"0","summary":"生物制药公司Theravance Biopharma宣布，其约7000万美元的全速运转成本节约计划预计将在第三季度全面落地。这一重要财务目标若能如期达成，将显著优化公司运营效率，为后续研发投入释放更多资金空间。\n成本控制举措的完整效益显现，标志着企业战略执行进入关键阶段。在当前生物科技行业融资环境趋紧的背景下，实现预期节流目标对维持现金流健康与研发持续性具有战略意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195682611","title":"Theravance Biopharma启动组织架构重组 旨在优化成本与资源配置","url":"https://stock-news.laohu8.com/highlight/detail?id=1195682611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195682611?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:35","pubTimestamp":1778157335,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. 宣布正式实施一项组织架构重组计划。该举措旨在系统性地精简运营成本，并使公司资源更高效地与其战略重点保持一致。此次重组预计将优化公司的财务结构，提升整体运营效率。\n通过这次调整，公司期望能够更灵活地应对市场变化，集中资源推进核心研发项目，为未来的长期增长奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118664421","title":"Theravance Biopharma成立战略评估委员会 积极寻求股东价值最大化方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1118664421","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118664421?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:31","pubTimestamp":1778157118,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc.（简称：Theravance Biopharma）已正式组建战略评估委员会，该委员会正全面评估各类战略机遇，旨在最大化股东价值。这一举措表明公司管理层正积极应对市场变化，致力于通过系统性评估为公司未来发展确定最优路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149115280","title":"Theravance Biopharma与Mylan获授权，可在2039年4月23日或之后于美国销售Yupelri仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1149115280","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149115280?lang=zh_cn&edition=full","pubTime":"2026-03-31 05:45","pubTimestamp":1774907113,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc.（简称Theravance Biopharma）宣布，该公司与Mylan已获得授权，允许其在2039年4月23日或之后在美国市场推出Yupelri的仿制版本。此项授权为两家公司未来进入相关药品市场铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163147414","title":"Theravance Biopharma与Mylan就Yupelri专利诉讼与Mankind达成和解协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1163147414","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163147414?lang=zh_cn&edition=full","pubTime":"2026-03-31 05:41","pubTimestamp":1774906873,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件显示，Theravance Biopharma Inc.及其合作单位已与Mylan公司共同就Yupelri相关专利诉讼与Mankind公司达成和解协议。该协议标志着三方围绕慢性阻塞性肺疾病治疗药物Yupelri的法律纠纷正式画上句号。\n此次和解避免了漫长诉讼可能带来的不确定性，为Theravance Biopharma聚焦核心药物研发扫清了障碍。作为一款用于维持慢性阻塞性肺病患者日常治疗的吸入式支气管扩张剂，Yupelri的市场前景备受行业关注。此次和解协议的达成，不仅保障了各方的商业利益，也为患者持续获得该创新疗法提供了稳定保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106818840","title":"Theravance Biopharma第四季度营业利润达2001.2万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106818840","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106818840?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:45","pubTimestamp":1773924310,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. (TBPH) 公布第四季度财务业绩。报告显示，该公司当季营业利润为2001.2万美元。\n在调整后的净利润方面，该公司实现313.1万美元，而此前IBES的预期为5830万美元，实际业绩显著低于市场预估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141259702","title":"修正：Theravance Biopharma第四季度营收4590万美元，低于IBES预估的5850万美元（金额已修正）","url":"https://stock-news.laohu8.com/highlight/detail?id=1141259702","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141259702?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:39","pubTimestamp":1773923980,"startTime":"0","endTime":"0","summary":"修正：Theravance Biopharma Inc. (TBPH) 公布第四季度财务数据，其营收为4590万美元，显著低于IBES分析师此前预估的5850万美元。此次公布为修正后的准确金额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157922473","title":"Theravance Biopharma股价盘前暴跌28%，高血压药物晚期试验未达主要终点，公司将启动战略评估","url":"https://stock-news.laohu8.com/highlight/detail?id=1157922473","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157922473?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:55","pubTimestamp":1772546114,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. (TBPH) 股价在盘前交易时段重挫28%，此前该公司宣布其研发的高血压药物在一项关键性晚期临床试验中未能达到主要研究目标。这一令人失望的试验结果直接触发了市场的大幅抛售。\n由于该药物未能实现预设的疗效终点，公司表示将立即对这款高血压药物的研发项目进行全面评估，并计划启动一项针对公司整体管线的战略审查。此次战略评估旨在重新规划研发资源的配置，并评估未来的发展路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196572960","title":"Theravance Biopharma Inc.宣布重大重组：研发部门完全解散，行政员工裁减约50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196572960","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196572960?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:32","pubTimestamp":1772544767,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. 公布了一项大规模重组计划，该计划的核心内容包括其研发（R&D）部门的完全解散，以及其行政（G&A）部门员工规模的大幅缩减，裁员幅度约为50%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199983267","title":"Theravance Biopharma三期Cypress研究未达主要终点 董事会加速战略评估并宣布成本削减措施","url":"https://stock-news.laohu8.com/highlight/detail?id=1199983267","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199983267?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:31","pubTimestamp":1772544676,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. (TBPH) 宣布，其针对慢性阻塞性肺病（COPD）患者的三期临床试验\"Cypress研究\"未能达到主要疗效终点。该研究旨在评估其在研药物在改善患者肺功能方面的效果。\n基于此临床结果，公司董事会决定加速推进全面的战略评估进程，以重新审视研发管线优先级及公司发展方向。同时，为优化运营效率，Theravance Biopharma将立即实施一系列成本削减措施，具体细节尚未披露。\n此次研发挫折可能对公司未来的产品商业化路径产生重要影响。市场将密切关注其后续战略调整及财务状况变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148610011","title":"Theravance Biopharma Inc. 重组有望带来约6000万至7000万美元年化现金流","url":"https://stock-news.laohu8.com/highlight/detail?id=1148610011","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148610011?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:31","pubTimestamp":1772544673,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. 宣布了一项重大重组计划，预计将使公司实现约6000万至7000万美元的年化现金流。这一举措旨在优化运营效率并加强财务状况，为未来的业务发展提供更稳固的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614302060","title":"Theravance Biopharma, Inc.盘中异动 股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614302060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614302060?lang=zh_cn&edition=full","pubTime":"2026-02-27 01:40","pubTimestamp":1772127622,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日01时40分，Theravance Biopharma, Inc.股票出现波动，股价急速下挫5.09%。Theravance Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为2.49%。其相关个股中，Curanex Pharmaceuticals Inc、Klotho Neurosciences Inc C/Wts 21/06/2029 、Liminatus Pharma Inc C/Wts 30/04/2030 涨幅较大，Curanex Pharmaceuticals Inc、Cardio Diagnostics Holdings Inc.、Kairos Pharma, Ltd.较为活跃，换手率分别为644.18%、104.87%、99.97%，振幅较大的相关个股有Curanex Pharmaceuticals Inc、Briacell Therapeutics Corp C/Wts 26/02/2026、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为59.81%、53.95%、50.06%。Theravance Biopharma, Inc.公司简介：Theravance Biopharma Inc 是一家多元化的生物制药公司，专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227014022a4cc6538&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227014022a4cc6538&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608818176","title":"Theravance Biopharma, Inc.盘中异动 下午盘大幅上涨5.23%报19.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608818176","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608818176?lang=zh_cn&edition=full","pubTime":"2026-02-03 02:28","pubTimestamp":1770056934,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日02时28分，Theravance Biopharma, Inc.股票出现波动，股价快速拉升5.23%。Theravance Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Psyence Biomedical Ltd.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Polyrizon Ltd.涨幅较大，Psyence Biomedical Ltd.、60 Degrees Pharmaceuticals, Inc.、Vivosim Labs, Inc.较为活跃，换手率分别为289.85%、270.07%、45.95%，振幅较大的相关个股有Psyence Biomedical Ltd.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Tuhura Biosciences, Inc.，振幅分别为217.09%、103.32%、46.29%。Theravance Biopharma, Inc.公司简介：Theravance Biopharma Inc 是一家多元化的生物制药公司，专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203022854953f7e18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203022854953f7e18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517427629","title":"Theravance Biopharma, Inc.盘中异动 大幅拉升5.16%报9.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517427629","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517427629?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:20","pubTimestamp":1741195237,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时20分，Theravance Biopharma, Inc.股票出现波动，股价急速拉升5.16%。Theravance Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.15%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为933.95%、303.15%、289.83%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Theravance Biopharma, Inc.公司简介：Theravance Biopharma Inc 是一家多元化的生物制药公司，专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012037989d6bab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012037989d6bab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516754802","title":"Theravance Biopharma, Inc.2024财年实现净利润-56.42百万美元，同比减少2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516754802","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516754802?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931279,"startTime":"0","endTime":"0","summary":"3月3日，Theravance Biopharma, Inc.公布财报，公告显示公司2024财年净利润为-56.42百万美元，同比减少2.23%；其中营业收入为64.38百万美元，同比增加12.12%，每股基本收益为-1.16美元。机构评级：截至2025年3月3日，当前有4家机构对Theravance Biopharma, Inc.目标价做出预测，其中目标均价为14.50美元，其中最低目标价为10.00美元，最高目标价为21.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000156a25bbc84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000156a25bbc84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.theravance.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0071},{"period":"3month","weight":0.0042},{"period":"6month","weight":-0.1098},{"period":"1year","weight":0.5108},{"period":"ytd","weight":-0.0989}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Theravance Biopharma, Inc.于2013年7月注册为开曼群岛豁免股份有限公司。该公司是一家生物制药公司，主要专注于药物的发现、开发和商业化。该公司的核心宗旨是创造能够改变人们生活的药物。该公司利用数十年的专业知识，开发了FDA批准的YUPELRI（revefenacin）吸入溶液，用于慢性阻塞性肺病患者的维持治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.019808},{"month":2,"riseRate":0.25,"avgChangeRate":0.006017},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.001894},{"month":4,"riseRate":0.583333,"avgChangeRate":0.039067},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.067072},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.016553},{"month":7,"riseRate":0.384615,"avgChangeRate":0.003583},{"month":8,"riseRate":0.666667,"avgChangeRate":0.01951},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.030285},{"month":10,"riseRate":0.5,"avgChangeRate":-0.025542},{"month":11,"riseRate":0.75,"avgChangeRate":0.113018},{"month":12,"riseRate":0.583333,"avgChangeRate":0.041602}],"exchange":"NASDAQ","name":"Theravance Biopharma Inc.","nameEN":"Theravance Biopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Theravance Biopharma Inc.(TBPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Theravance Biopharma Inc.(TBPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Theravance Biopharma Inc.,TBPH,Theravance Biopharma Inc.股票,Theravance Biopharma Inc.股票老虎,Theravance Biopharma Inc.股票老虎国际,Theravance Biopharma Inc.行情,Theravance Biopharma Inc.股票行情,Theravance Biopharma Inc.股价,Theravance Biopharma Inc.股市,Theravance Biopharma Inc.股票价格,Theravance Biopharma Inc.股票交易,Theravance Biopharma Inc.股票购买,Theravance Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Theravance Biopharma Inc.(TBPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Theravance Biopharma Inc.(TBPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}